CLINICAL & PIPELINE·Drug Approval
Teva Pharmaceuticals Secures FDA Labeling Approval for Discontinued Oxaliplatin Injectable (NDA022160)
Teva Pharmaceuticals has received FDA approval for a supplemental labeling application (submission 16) for its Oxaliplatin injectable (NDA022160) on October 31, 2024. Despite this regulatory update, both 50MG/10ML and 100MG/20ML strengths of Teva's Oxaliplatin are officially listed as "Discontinued" by the FDA, indicating no active market presence for this specific product.
90-Day Activity